ASSAY METHOD FOR ALZHEIMER'S DISEASE
First Claim
Patent Images
1. A method to diagnose preclinical or clinical Alzheimer'"'"'s disease in a subject, which method comprises administering to said subject an amount of an antibody which specifically binds an epitope contained within positions 13-28 of Aβ
- or an antibody that sequesters Aβ
peptide from its bound, circulating form in the blood and alters clearance of soluble and bound forms of Aβ
in the central nervous system in plasma;
effective to alter the levels of circulating Aβ
peptides in the blood of said subject when said subject is in a preclinical or clinical stage of Alzheimer'"'"'s disease, followed by measuring the level of, Aβ
40, Aβ
42, or the ratio of Aβ
40/Aβ
42 in the blood of said subject at a time interval after said administering; and
comparing the level of Aβ
40, Aβ
42, or the ratio of Aβ
40/Aβ
42 in said subject with a control value of said levels, wherein differing levels of Aβ
40, Aβ
42 or Aβ
40/Aβ
42 ratio in said subject as compared to control levels or ratio identifies said subject as in a preclinical or clinical stage of Alzheimer'"'"'s disease.
6 Assignments
0 Petitions
Accused Products
Abstract
A diagnostic test for preclinical and clinical Alzheimer'"'"'s disease is based on plasma levels of Aβ40, Aβ42, their ratio, or their rate of entry following administration of antibodies that sequester Aβ. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer'"'"'s disease.
37 Citations
15 Claims
-
1. A method to diagnose preclinical or clinical Alzheimer'"'"'s disease in a subject, which method comprises administering to said subject an amount of an antibody which specifically binds an epitope contained within positions 13-28 of Aβ
- or an antibody that sequesters Aβ
peptide from its bound, circulating form in the blood and alters clearance of soluble and bound forms of Aβ
in the central nervous system in plasma;
effective to alter the levels of circulating Aβ
peptides in the blood of said subject when said subject is in a preclinical or clinical stage of Alzheimer'"'"'s disease, followed by measuring the level of, Aβ
40, Aβ
42, or the ratio of Aβ
40/Aβ
42 in the blood of said subject at a time interval after said administering; and
comparing the level of Aβ
40, Aβ
42, or the ratio of Aβ
40/Aβ
42 in said subject with a control value of said levels, wherein differing levels of Aβ
40, Aβ
42 or Aβ
40/Aβ
42 ratio in said subject as compared to control levels or ratio identifies said subject as in a preclinical or clinical stage of Alzheimer'"'"'s disease. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- or an antibody that sequesters Aβ
-
13. A kit for the diagnosis of clinical or preclinical Alzheimer'"'"'s disease in a subject which comprises a container containing an antibody which specifically binds an epitope contained within positions 13-28 of Aβ
- or an antibody that sequesters Aβ
peptide from its bound, circulating form in the blood and alters clearance of soluble and bound forms of Aβ
in the central nervous system and in plasma and instructions for administering the antibody. - View Dependent Claims (14, 15)
- or an antibody that sequesters Aβ
Specification